Clinical impact of a new automated system employed for peripheral blood stem cell collection.
At the moment, PBSC collections can be performed using semi-automated or automated cell separator devices. The automated methods offer the advantages of a decreased working load for dedicated personnel and high standardization of the collection procedure. Herein we report our single institutional experience in 80 PBSC collections employing the new automated COM.TEC Fresenius autoMNC program that provides the ability to predict the total number of CD34(+) cells collected, based on the pre-leukapheresis CD34(+) cell count in peripheral blood. Fourty-eight patients and 21 healthy donors were mobilized with chemotherapy + G-CSF or G-CSF alone, respectively. Eighty leukapheresis collections were performed starting with a CD34(+) cell count in peripheral blood at least of 20/microL. Collection parameters and related side effects were evaluated. The mean CD34(+) cell collection efficiency in patients and donors was 81.8% (sd 27.6) and 95.1% (sd 15.6), respectively. The mean difference between real and predicted CD34(+) cells was +30.2% (sd 92.9) for patients and +4.6% (sd 30.3) for donors. The mean leukapheresis bag volume was 240.7 ml (sd 67.3) and 310.3 ml (sd 86.8) with a mean HCT of 10.9% (sd 34.4) and 9.2% (sd 3.9) for patients and donors, respectively. The automated PBSC collection with the new program COM.TEC Fresenius autoMNC demonstrated a very high CD34(+) cell collection efficiency. Moreover, the ability to predict the CD34(+) cell yield permits improved management of the leukapheresis collection, with the only disadvantage of larger leukapheresis volume and higher hematocrit.
Del Fante
Claudia
C
Immunohaematology and Transfusion Service, Center for Transplant Immunology, IRCCS Policlinico S. Matteo, Pavia, Italy.
Perotti
Cesare
C
Viarengo
Gianluca
G
Bellotti
Laura
L
Parisi
Cristina
C
Marchesi
Andrea
A
Tinelli
Carmine
C
Salvaneschi
Laura
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000097:blood / Q000628:therapy; D018952:Antigens, CD34 / Q000032:analysis; D001331:Automation; D001772:Blood Cell Count; D001782:Blood Donors; D001943:Breast Neoplasms / Q000097:blood / Q000628:therapy; D002648:Child; D003114:Colony-Forming Units Assay; D005260:Female; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D019337:Hematologic Neoplasms / Q000097:blood / Q000628:therapy; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000737:chemistry; D006801:Humans; D007937:Leukapheresis / Q000295:instrumentation*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation
D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor